AR127858A1 - NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE ÓMICRON STRAIN OF SARS-CoV-2 - Google Patents
NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE ÓMICRON STRAIN OF SARS-CoV-2Info
- Publication number
- AR127858A1 AR127858A1 ARP220103320A ARP220103320A AR127858A1 AR 127858 A1 AR127858 A1 AR 127858A1 AR P220103320 A ARP220103320 A AR P220103320A AR P220103320 A ARP220103320 A AR P220103320A AR 127858 A1 AR127858 A1 AR 127858A1
- Authority
- AR
- Argentina
- Prior art keywords
- cov
- sars
- strain
- nucleic acid
- sequences derived
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title abstract 3
- 241000711573 Coronaviridae Species 0.000 title abstract 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title 1
- 229940023146 nucleic acid vaccine Drugs 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 108700021021 mRNA Vaccine Proteins 0.000 abstract 1
- 229940126582 mRNA vaccine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Moléculas de ácido nucleico terapéutico para gestionar, prevenir y/o tratar enfermedades infecciosas causadas por el coronavirus. También composiciones terapéuticas, que incluyen vacunas y nanopartículas lipídicas, que comprenden los ácidos nucleicos terapéuticos y los métodos y usos terapéuticos relacionados. En particular, vacunas de ARNm basadas en secuencias derivadas de la cepa Ómicron del SARS-CoV-2. Reivindicación 1: Un ácido nucleico artificial caracterizado porque comprende una secuencia de nucleótidos codificante que codifica el dominio de unión al receptor (RBD) de la proteína de la espícula (S) de la cepa Ómicron del SARS-CoV-2, o un fragmento de la misma, donde el RBD consiste en, consiste esencialmente en o comprende la secuencia de aminoácidos establecida en SEQ ID Nº 60.Therapeutic nucleic acid molecules to manage, prevent and/or treat infectious diseases caused by coronavirus. Also therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses. In particular, mRNA vaccines based on sequences derived from the Omicron strain of SARS-CoV-2. Claim 1: An artificial nucleic acid characterized in that it comprises a coding nucleotide sequence that encodes the receptor binding domain (RBD) of the spike (S) protein of the Omicron strain of SARS-CoV-2, or a fragment of the same, where the RBD consists of, consists essentially of or comprises the amino acid sequence set forth in SEQ ID NO: 60.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021135446 | 2021-12-03 | ||
| CN2021141075 | 2021-12-24 | ||
| CN2022076393 | 2022-02-16 | ||
| CN2022122380 | 2022-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127858A1 true AR127858A1 (en) | 2024-03-06 |
Family
ID=86611543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103320A AR127858A1 (en) | 2021-12-03 | 2022-12-02 | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE ÓMICRON STRAIN OF SARS-CoV-2 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN117580587A (en) |
| AR (1) | AR127858A1 (en) |
| WO (1) | WO2023098842A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023511633A (en) * | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | coronavirus RNA vaccine |
| CA3177940A1 (en) * | 2020-05-07 | 2021-11-11 | Anusha DIAS | Optimized nucleotide sequences encoding sars-cov-2 antigens |
| MX2022014167A (en) * | 2020-05-11 | 2023-02-14 | Janssen Pharmaceuticals Inc | Rna replicon encoding a stabilized corona virus spike protein. |
| WO2021159130A2 (en) * | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
| US10906944B2 (en) * | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
-
2022
- 2022-12-02 WO PCT/CN2022/136053 patent/WO2023098842A1/en active Application Filing
- 2022-12-02 AR ARP220103320A patent/AR127858A1/en unknown
- 2022-12-02 CN CN202280006456.1A patent/CN117580587A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023098842A1 (en) | 2023-06-08 |
| CN117580587A (en) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39060A (en) | COMPOSITIONS AND METHODS TO PREVENT AND TREAT CORONAVIRUS INFECTION - SARS-COV-2 VACCINES | |
| ES2542853T3 (en) | Method to treat myasthenia gravis | |
| AR107020A2 (en) | PCSK9 VACCINE (SUBTILISINE-KEXINA TYPE 9 CONVERTASE PROTEIN) | |
| CR20190276A (en) | Novel t cell receptors and immune therapy using the same | |
| AR125394A2 (en) | METHODS AND COMPOSITIONS FOR GENE EXPRESSION IN PLANTS | |
| AR127858A1 (en) | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE ÓMICRON STRAIN OF SARS-CoV-2 | |
| ES2668926T3 (en) | RNA composition for the treatment of non-small cell lung cancer (NSCLC) | |
| CL2009001001A1 (en) | Anti-complement factor d antibody; coding polynucleotide; vector comprising said polynucleotide; host cell comprising said vector; method of making the antibody; pharmaceutical composition comprising it; use of the antibody to treat inflammatory disorders or eye disorders. | |
| CL2019000732A1 (en) | Huntington's disease avv treatment. | |
| CO5700788A2 (en) | COMPOSITIONS AND METHODS FOR SPECIFIC IMMUNOTHERAPY OF WT1 | |
| CO2021007916A2 (en) | Ribonucleic acid (RNA) that codes for a protein | |
| AR083740A1 (en) | DKK1 ANTIBODIES (DICKKOPF-1) AND METHODS OF USE | |
| AR065289A1 (en) | ACTIVINA ANTAGONISTS - ACTRIA AND ITS USES FOR THE PROMOTION OF OSEO GROWTH AND MULTIPLE MYELOMA TREATMENT | |
| ITMI20021527A1 (en) | C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE | |
| AR109538A1 (en) | VACCINE AGAINST THE SWINE FLU | |
| CO2017012454A2 (en) | Uricase sequences suitable for the treatment of hyperuricemia | |
| PE20230171A1 (en) | VACCINES AGAINST CORONAVIRUS AND METHODS OF USE | |
| AR112166A1 (en) | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B | |
| CO2019013220A2 (en) | Oncolytic viruses and method | |
| AR079813A1 (en) | METHODS TO CONTROL THE NEMATOD OF ROOT INJURIES | |
| NZ741841A (en) | Antisense oligonucleotides for use in treating alzheimer’s disease | |
| DK200300821A (en) | Process for in vitro molecular evolution of protein function | |
| US20190185820A1 (en) | Compositions and Methods for Inhibiting Stem Cell Aging | |
| CO6362049A2 (en) | PEPTIDO-EPITOPE RAB6KIFL / KIF20A AND VACCINES CONTAINING THE SAME | |
| AR127311A1 (en) | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM THE DELTA STRAIN OF SARS-CoV-2 |